A randomized, placebo-controlled, double-blind, phase 3 study evaluating the pain palliation benefit of adding custirsen to a taxane for second-line chemotherapy in men with castrate resistance prostate cancer

Trial Profile

A randomized, placebo-controlled, double-blind, phase 3 study evaluating the pain palliation benefit of adding custirsen to a taxane for second-line chemotherapy in men with castrate resistance prostate cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Custirsen (Primary) ; Cabazitaxel; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SATURN
  • Sponsors OncoGenex Pharmaceuticals
  • Most Recent Events

    • 11 Feb 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 01 Feb 2014 Results presented at the 2014 Genitourinary Cancers Symposium.
    • 08 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top